Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052388 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
A Phase 2 study of Bacterial Infection and Skin Infection, sponsored by Cellceutix Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
- 4
- Study locations
NCT02052388 is a Phase 2 study of Bacterial Infection and Skin Infection that has completed, run by Cellceutix Corporation. The registered enrollment target is 215 participants, above the 79-participant average among 8 other Bacterial Infection trials with a reported enrollment target (172% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT02052388, a Phase 2 study of Bacterial Infection and Skin Infection, has completed, sponsored by Cellceutix Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
Conditions Studied
Interventions
- DRUG Daptomycin
- DRUG Brilacidin
Study Locations (4)
California
- eStudy Site - Chula Vista
- eStudy Site - La Mesa
- eStudy Site - Oceanside
Nevada
- eStudy Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052388
The ClinicalTrials.gov registry entry for NCT02052388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 8 other Bacterial Infection trials with a reported enrollment target (172% higher). The listed sponsor is Cellceutix Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bacterial Infection appearing as the primary indexed condition, and to 2 interventions - of which Daptomycin is the first listed.
NCT02052388 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Nevada.
Frequently Asked Questions
What is clinical trial NCT02052388 about?
NCT02052388 is a clinical study titled "Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections". The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
What is the current status of trial NCT02052388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2014-02. Estimated completion is 2014-10.
What conditions does trial NCT02052388 study?
This clinical trial studies the following conditions: Bacterial Infection, Skin Infection.
What interventions are being tested in trial NCT02052388?
The interventions under investigation include: Daptomycin (DRUG), Brilacidin (DRUG).
Who is sponsoring clinical trial NCT02052388?
This trial is sponsored by Cellceutix Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02052388 being conducted?
This trial has 4 study locations across California, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
COMPLETED · Phase 2
-
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
COMPLETED · Phase 2
-
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
RECRUITING · Phase 4
-
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
RECRUITING · Phase 4
-
Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm
COMPLETED · NA
-
Safety of Intravenous Apramycin in Adults
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.